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The goal of this project was to better define the relationship between the endoribonuclease activity of murine
hepatitis virus (MHV) Nsp15 (mNsp15) and its role in virus infection. Molecular modeling demonstrated that
the catalytic residues of mNsp15 are superimposable with its severe acute respiratory syndrome coronavirus
ortholog. Alanine substitutions at three key residues in the mNsp15 catalytic pocket (H262, H277, and G275)
and a double-mutant version (H262P and H277A) generated proteins with greatly reduced but detectable
endoribonuclease activities. Furthermore, these mutant proteins demonstrated lower cleavage specificities for
uridylate than wild-type (WT) mNsp15. These mutations were successfully incorporated into viruses named
vH262A, vH277A, vG275A, and vH262PH277A. All four mutant viruses formed plaques with diameters
similar to that of MHV-A59 1000 (WT virus) on several different cell lines. Interestingly, viruses with a
mutation at a noncatalytic residue, D324A, could not be recovered despite repeated attempts, and expression
of mNsp15 containing the D324A mutation in Escherichia coli resulted in an insoluble protein. Plaques derived
from vH262A produced approximately 6- to 13-fold fewer PFU than those from WT virus. Cells infected with
mNsp15 mutant viruses accumulated lesser amounts of plus- and minus-sense subgenomic RNAs and spike
protein than WT virus. The expression of mNsp15 in trans by transient transfection partially restored RNA
synthesis by vH262A. These results demonstrate that mNsp15 is required for optimal infection by MHV.
Coronaviruses are significant pathogens of humans and an-
imals. They are also interesting because they use replication
mechanisms that are unusual among the positive-stranded
RNA viruses (18). For example, coronaviruses produce minus-
strand subgenomic RNAs (sgRNAs) by a discontinuous tran-
scription mechanism and utilize these as templates for sub-
genomic mRNA (sgmRNA) synthesis (18, 22). In addition, the
viral genome encodes a number of proteins that are not typi-
cally found in the positive-strand RNA viruses, including a
potential RNA primase and several RNA-processing enzymes
such as ExoN, XendoU, and cap methyltransferases (20, 24–26,
32).
One of these novel RNA-processing enzymes is nonstruc-
tural protein 15 (Nsp15), a hexameric endoribonuclease that
preferentially cleaves 3 of uridylates (12, 21, 28). Severe acute
respiratory syndrome coronavirus (SARS-CoV) recombinant
Nsp15 (sNsp15) produced in Escherichia coli has endoribo-
nuclease activity that is stimulated by Mn2, generating a 2,3
cyclophosphodiester cleavage product (2, 3). The structure of
sNsp15 was first determined by electron microscopy and then
by X-ray crystallography (3, 21). The structure of murine hep-
atitis virus (MHV) Nsp15 (mNsp15) was also recently solved
(28). A mutation (D6408A) in the Nsp15 coding sequence of
human coronavirus (HCoV) 229E prevented viral RNA accu-
mulation, suggesting that HCoV-229E Nsp15 is required for
viral replication (12).
Both the arterivirus and coronavirus families are members of
the order Nidovirales and encode orthologs of Nsp15 (NendoU)
endoribonuclease (9, 19). A thorough analysis of mutations in
the ortholog of NendoU in the arterivirus equine arteritis virus
(EAV) revealed that the endoribonuclease exerts significant
and pleiotropic effects on EAV replication (19). Several mu-
tations, including mutations in the putative active site (H2693
and H2978), reduced viral plaque formation significantly but
did not abolish EAV infection in cultured cells. Other muta-
tions, including D3014A, which corresponds to the D6408A
mutation in HCoV-229E Nsp15, were lethal to EAV replica-
tion and abolished EAV infection. The complex phenotypes
conferred by the mutant viruses suggest that Nsp15 may have
more than one role in the replicative cycles of coronaviruses
and their relatives.
Murine coronaviruses have provided good model systems for
studies of multiple sclerosis, virus-induced demyelination,
acute and chronic hepatitis, gastroenteritis, and pneumonitis
(4–6, 11, 15, 27). Recent phylogenetic studies, including a com-
parison of an extensive set of amino acid sequences, revealed
that SARS-CoV is best placed as an early branch of the group
2 coronaviruses, which includes MHV (9, 26). MHV strain
1-infected A/J mice develop a severe pulmonary infection char-
acterized by congestion, pulmonary infiltrates, formation of a
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hyaline membrane, and hemorrhage, symptoms similar to
those caused by SARS-CoV in humans (4, 5). Moreover, the
RNA cis-acting elements, such as the 3 untranslated region (3
UTR) and stem-loops in the 5 UTR, of SARS-CoV can func-
tionally substitute for their counterparts in MHV-A59, con-
firming a close phylogenetic relationship between SARS-CoV
and MHV (8, 13, 14). Taken together, these results suggest
that MHV is an excellent model system for in vivo studies of
SARS-CoV pathogenesis.
The goal of this study was to determine whether mNsp15
endoribonuclease activity is required for the MHV infection
process. We produced wild-type (WT) and mutant mNsp15
and examined the requirements for its active-site residues in
RNA cleavage in vitro. We also generated MHVs containing
mutations in mNsp15 and found that the mNsp15 mutant vi-
ruses were defective for viral infection in permissive cells,
especially in viral RNA accumulation. Lastly, we demonstrated
that WT mNsp15 can partially complement both the RNA
accumulation and the infectivity of mutant MHV in trans.
MATERIALS AND METHODS
Bacteria, viruses, and cells. E. coli strain Top10 (Gibco-BRL), which was used
for DNA manipulations, was cultured at 37°C in Luria-Bertani and 2 yeast
extract-tryptone media. DBT and 17CL-1 cells were maintained at 37°C under
5% CO2 in Dulbecco’s modified Eagle medium (DMEM) supplemented with
10% calf serum (HyClone, Logan, UT). L2 cells were maintained at 37°C under
3% CO2 in DMEM supplemented with 10% calf serum. BHK-21 baby hamster
kidney cells expressing the MHV receptor (BHK-R) were grown in minimal
essential medium supplemented with 10% calf serum and G418 (800 g/ml) to
select for cells expressing the MHV receptor.
Recombinant Nsp15. Recombinant Nsp15 containing an N-terminal His6 tag
was expressed in E. coli and purified using immobilized metal affinity chroma-
tography followed by Mono Q ion-exchange chromatography as previously de-
scribed (2). Site-directed mutations in Nsp15 cDNA were made with the
QuikChange II site-directed mutagenesis kit (Stratagene, San Diego, CA). The
entire cDNA was sequenced to ensure that only the intended mutation was
introduced.
Endoribonuclease assays. RNAs used for endoribonuclease assays were chem-
ically synthesized by Dharmacon, Inc. (Boulder, CO) and contain the SARS-
CoV transcription regulatory sequence (TRS) (5-CAACU/AAACGAAC [the
slash indicates the expected cleavage site]) for sgmRNA3, encoding the spike (S)
protein. RNAs used in the gel-based endoribonuclease assays were labeled at
their 5 termini with [-32P]ATP and T4 polynucleotide kinase according to the
protocol described previously (2).
The standard RNA cleavage assay mixture contained 1 M RNA (1  104
cpm) in buffer A (50 mM Tris [pH 7.5], 50 mM KCl, 1 mM dithiothreitol, and 5
mM MnCl2) at 30°C. The endoribonuclease reactions were terminated by the
addition of a gel-loading buffer containing 7.5 M urea. Products were separated
by electrophoresis in gels composed of 7.5 M urea and 20% polyacrylamide. Gels
were wrapped in plastic and exposed to a PhosphorImager screen for quantifi-
cation using Molecular Dynamics software. Each result shown was reproduced in
at least two independent experiments.
The real-time endoribonuclease assay used a substrate from Integrated DNA
Technologies, Inc. (Coralville, IA). The substrate has a carboxyfluorescein
(FAM) fluorophore at the 5 end and tetramethylrhodamine (TAMRA), which
quenches FAM fluorescence, at the 3 end. The substrate contains only 4 nucle-
otides (nt), of which 3 are deoxyribonucleotides while 1 is a ribonucleotide that
is a potential cleavage site for Nsp15. The excitation wavelength was 492 nm, and
the maximum emission of the substrate at 518 nm was determined in buffer A.
Changes in fluorescence were measured over time using a BMG plate reader.
Molecular modeling. The molecular docking program Dock 6.0 was used to
perform flexible docking of 3-UMP (from Protein Data Bank [PDB] identifica-
tion number [ID] 4RSK; RNase A:3-UMP complex structure) into the mNsp15
crystal structure (PDB ID 2GTH), which was kept rigid. A set of spheres that
represent the negative image of the binding site were defined within the 10-Å
radius of the catalytic-site residues H262, H277, K317, and T321 of mNsp15
protein to adopt the sphere-matching algorithm of Dock 6.0. Incremental con-
struction (anchor-and-grow method) was used to allow the flexibility of the
ligand. The automatic matching mode was used with 20 configurations per ligand
building cycle. Interaction between the ligand and the receptor was evaluated by
the grid score (a combination of van der Waals and electrostatic components)
and visual inspection. The interhydrogen bonds between the highest-ranked
3-UMP and the catalytic-site residues of mNsp15 were further refined by minor
manual model building using Xfit (16).
The atomic coordinates of the WT mNsp15 crystal structure (28) (PDB ID
2GTH) were used to construct a model of the mNsp15 G275A mutant with
Modeler (Insight II; Accelrys). Residues within a 10-Å radius of A275 were
subjected to a simulated annealing optimization with respect to the variable
target function of Modeler. The figures were prepared using USCF Chimera
(http://www.cgl.ucsf.edu/chimera/).
Construction of plasmids used in an MHV reverse-genetic system. The prim-
ers and plasmids used in this study are listed in Tables 1 and 2, respectively. The
F plasmid of the MHV-A59 1000 reverse-genetic system containing the mNsp15
cDNA sequence (30) was used to introduce mutations into mNsp15. Briefly, the
3.38-kb BamHI-HpaI fragment of the F plasmid was amplified and cloned into
the pGEM-T vector (Promega, Madison, WI) to produce pWtNsp15-PG. This
plasmid harbors sequences of open reading frames for MHV Nsp15, Nsp16, and
2a protein. Using the QuikChange II site-directed mutagenesis kit (Stratagene,
Inc., La Jolla, CA) according to the manufacturer’s instructions, mutations
H262A, G275A, H277A, and D324A were introduced into mNsp15 of pWtNsp15-
PG to yield p1F-PG, p2F-PG, p3F-PG, and p4F-PG, respectively. The sequences
of BamHI-HpaI fragments carrying single mutations in mNsp15 were deter-
mined in order to confirm that the desired sequences were obtained. The
BamHI-HpaI fragments containing the mutations were excised and religated into
BamHI-HpaI-digested plasmid F, and the ligation products were then trans-
formed into the Top10 strain of E. coli. The region of the recovered clones
between the BamHI and HpaI sites was sequenced again to verify that the
desired mutation was recovered.
Recovery of mNsp15 mutant viruses. The reverse genetic system for MHV-
A59 1000 used in this study was initially described by Yount et al. (30). cDNAs
representing the entire MHV-A59 genome containing either the mNsp15 WT
sequence or a mutant sequence were constructed by ligation of A and G cloned
cDNAs as described previously (30). WT genomes containing mNsp15 WT and
mutant sequences were transcribed in vitro and electroporated into BHK-R cells
as previously described (30). Cultures were observed for as long as 72 h postin-
fection (hpi) for the development of cytopathic effects (CPE), which consist
mainly of syncytium formation. Virus-infected cultures were then harvested and
frozen at 70°C. Mutant viruses were subjected to one round of plaque purifi-
cation and were amplified once in DBT cells to generate stocks for additional
characterizations. The sequences of recovered viruses corresponding to the 5
and 3 UTRs, as well as the portions encoding mNsp15 mutant proteins, were
amplified by reverse transcription-PCR (RT-PCR), followed by direct sequenc-
ing of the amplified products.
Plaque assays. In order to determine growth curves for mNsp15 mutant
viruses, DBT cells were grown in 96-well plates, and replicate wells were infected
at a multiplicity of infection (MOI) of either 0.5 or 1.5 with mNsp15 mutant
viruses or MHV-A59 1000 (WT virus). After the inocula were washed away,
cultures were incubated until 0, 4, 8, 12, 16, or 24 hpi, at which time they were
frozen at 70°C. Triplicate samples were obtained for all time points. Virus
production was quantified by plaque assays on monolayers of L2 cells. The two
growth curves were done with independent isolates. Isolated plaques were re-
suspended and titered on L2, 17CL-1, and DBT cells. The diameters of the
resultant plaques were determined and compared with those formed by the WT
virus.
Analysis of viral RNA accumulation. DBT cells (2.25  105 per well) were
seeded into 12-well plates and incubated at 37°C for 15 h to reach approximately
2.5  105 cells per well. Replicate cultures were then infected with either WT
virus or viruses carrying mutations in mNsp15 at an MOI of 1, further incubated
for 6 h, washed twice with phosphate-free DMEM, fed with DMEM supple-
mented with 2% dialyzed calf serum and 10 g/ml of actinomycin D, and
incubated at 37°C. Following a 15-min incubation, the medium was replaced with
a phosphate-free medium containing 10 g/ml actinomycin D, 2% dialyzed
serum, and 200 Ci/ml 32PO4 and was incubated at 37°C for 5.5 h, by which time
90% of the cells infected with WT virus had formed syncytial giant cells. The
labeled cultures were washed twice with cold phosphate-buffered saline, and
RNA was extracted using an RNeasy minikit (Qiagen). The amount of RNA in
each sample was measured using the RediPlate 96 RiboGreen RNA quantitation
kit (Invitrogen Inc.). Equal amounts of radiolabeled viral RNA were denatured
in formaldehyde gel-loading buffer containing ethidium bromide (20 g/ml) at
65°C for 15 min and then electrophoresed through a 1% formaldehyde-agarose
gel at 100 V for 6 h. Following electrophoresis, the gel was illuminated with UV
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light, the image was captured with a FluorChem 8900 (Alpha Innotech, San
Leandro, CA) imaging system, and the relative amount of 28S rRNA bands was
determined by densitometry. The gel was soaked in 70% methanol for 30 min,
dried over a vacuum, and exposed to X-ray film. The amounts of radiolabel in
individual sgRNAs and the genomic RNA (gRNA) were determined by exposing
the dried gel to a Molecular Dynamics PhosphorImager equipped with Storm 8.2
software. The 28S rRNA in each sample was used to normalize the
PhosphorImager signals to account for small differences in the amount of RNA
loaded per sample.
Quantitative RT-PCR (RT-qPCR) was used to determine the effect of the
H262A mutation on MHV minus-strand RNA accumulation. DBT cells (4 
105) were seeded in parallel T25 flasks, incubated at 37°C for 48 h under 5%
CO2, and then infected with either the H262A mutant or WT virus at an MOI of
0.5. Total RNAs were extracted at 8 and 12 hpi, and 2 g of the RNA was
subjected to Superscript II RNase H-reverse transcriptase (Invitrogen Inc.) in
the presence of a primer specific for MHV minus-strand RNAs (primer MHV 5
1-20 [Table 1]). The resultant reverse transcription products were purified using
a QIAquick PCR purification kit (Qiagen Inc., Valencia, CA), and 5% of the
product was subjected to amplification with antisense primers specific for MHV
RNA1, sgRNA3, and sgRNA7. The levels of the products were quantified with
iQ SYBR Green Supermix (Bio-Rad, Philadelphia, PA). Primers used to spe-
cifically prime MHV minus-strand RNA1 and sgRNA3 and -7 are listed in Table
1. The level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in each
sample was used as the internal control in each qPCR. A negative control in the
absence of primers was performed for each reaction.
Accumulation of S protein during MHV infection. DBT cells (2.5  105 per
well) were seeded onto 12-well plates, incubated at 37°C for 12 h under 5% CO2,
and infected with either an mNsp15 mutant or WT virus at an MOI of 1. At 8 and
TABLE 1. Primers used in this study
Primer Sequence (533)a
H262A_SD_F ...................................................................................GGACTACGCGTTTGAAgcCGTTGTTTATGGTAGTTTTAACC
H262A_SD_R ..................................................................................GGTTAAAACTACCATAAACAACGGCTTCAAACGCGTAGTCC
G275A_SD_F ...................................................................................CCAGAAGATTATTGGAGcTTTGCATTTGCTTATTGGCTTAGCCC
G275A_SD_R...................................................................................GGGCTAAGCCAATAAGCAAATGCAAAGCTCCAATAATCTTCTGG
H277A_SD_F ...................................................................................CCAGAAGATTATTGGAGGTTTGgcTTTGCTTATTGGCTTAGCCC
H277A_SD_R ..................................................................................GGGCTAAGCCAATAAGCAAAGCCAAACCTCCAATAATCTTCTGG
D324A_SD_F ...................................................................................GTAAGAGTGTGTGCACTGTTATTGCTTTATTGTTAGATGATTTTGTGG
D324A_SD_R...................................................................................CCACAAAATCATCTAACAATAAAGCAATAACAGTGCACACACTCTTAC
Oligonucleotide 35-5_R ..................................................................GCT CGG ATC CAC TAG TAA CGG CCG CCA GTG
Oligonucleotide 28-1_F...................................................................GTA TGT TAA CAA ACA TGC ATT CCA CAC C
MHVpcdna-ab ..................................................................................AAAAGGTACCATGGGTTTAGAAAATGTAGTG
MHVpcdna-bc ..................................................................................CGAAGGATCCTACAGATCCTCTTCAGAGATGAGTTTCTGCTCCTGCAA
ACGAGGATAGAAAGTCATGACCTTCTC
MHV 5 1-20 () ............................................................................TATAAGAGTGATTGGCGTCC
7059 () oligonucleotide 8d ...........................................................CTGGTGTTACACAGGCAG
S_seq_R1 primere ............................................................................ATTGCTGAGCGTAAACAACG
N () primerf...................................................................................GGC ACT CCT TGT CCT TCT
B35For ..............................................................................................TAG TAC TCT ACC TGG TTT T
17TG .................................................................................................TTT TTT TTT TTT TTT TTG
GAPDH-F2 primer .........................................................................ACCCAGAAGACTGTGGATGG
GAPDH-R2 primer.........................................................................CACATTGGGGGTAGGAACAC
a Lowercase letters indicate mutations.
b Sense primer containing a KpnI site, A at 3, a start codon (ATG), and G at 4 to replace S with G.
c Antisense primer with a Myc tag, a stop codon (TGA), and BamHI site.
d Corresponding to nt 611 to 628 in the MHV-A59 genome (GenBank accession number NC001846); used to specifically prime minus-strand sgRNA1.
e Corresponding to nt 25320 to 25339 in the MHV-A59 genome; used to specifically prime minus-strand sgRNA3.
f Corresponding to nt 29920 to 29937 in the MHV-A59 genome; used to specifically prime minus-strand sgRNA7.
TABLE 2. Plasmids used in this study
Plasmid Description
Plasmid Fa................................................................................................PCR-XL-Topo vector containing a 6.9-kb DNA fragment of MHV cDNA
(bp 15755–22739 on the MHV-A59 genome)
pWtNsp15-PG .........................................................................................pGEM-T (Promega, Madison, WI) containing a PCR product corresponding
to a 3.4-kb BamHI-HpaI fragment in plasmid F of MHV cDNA
p1F-PG.....................................................................................................pWtNsp15-PG containing an H262A mutation in mNsp15
pHK1Fb ....................................................................................................Plasmid F containing the mNsp15 H262A mutation
p2F-PG.....................................................................................................pWtNsp15-PG containing a G275A mutation in mNsp15
pHK2F......................................................................................................Plasmid F containing the mNsp15 G275A mutation
p3F-PG.....................................................................................................pWtNsp15-PG containing an H277A mutation in mNsp15
pHK3F......................................................................................................Plasmid F containing the mNsp15 H277A mutation
p4F-PG.....................................................................................................pWtNsp15-PG containing a D324A mutation in mNsp15
pHK4F......................................................................................................Plasmid F containing the mNsp15 D324A mutation
pcD-mNsp15 ............................................................................................pcDNA1 (Invitrogen, Carlsbad, CA) containing mNsp15 coding sequence
pcD-sNsp15..............................................................................................pcDNA1 containing sNsp15 coding sequence
pcD-GFP-sNsp15 ....................................................................................pcDNA1 containing GFP conjugated to the N terminus of the mNsp15
coding sequence
a One of seven plasmids used in the MHV-A59 reverse-genetic system (30).
b The BamHI-HpaI fragment containing the H262A mutation in p1F-PG was excised and religated into BamHI-HpaI-digested plasmid F to construct pHK1F.
Plasmids pHK2F, pHK3F, and pHK4F were constructed using p2F-PG, p3F-PG, and p4F-PG, respectively, with the same protocol as that for the construction of
pHK1F.
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10 hpi, total proteins were harvested as described previously (31). Total protein
(2 g per lane) was electrophoresed on sodium dodecyl sulfate-polyacrylamide
gels and transferred to nitrocellulose membranes for Western blotting as de-
scribed previously (31). Protein was detected with goat anti-MHV S protein
antibodies (kindly provided by K. Holmes), horseradish peroxidase (HRP)-con-
jugated anti-goat immunoglobulin G (IgG) antibodies, and the Immobilon West-
ern Detection reagents (Millipore, Billerica, MA) according to the manufactur-
er’s recommendations. As an internal control, GAPDH was detected using a
mouse primary antibody (Alpha Diagnostics, San Antonio, TX) and HRP-con-
jugated anti-mouse IgG as a secondary antibody (Santa Cruz Biotechnology,
Santa Cruz, CA).
trans-Complementation assay. DNA fragments encoding mNsp15 and sNsp15
were amplified using sense and antisense primers that harbored BamHI and
KpnI restriction sites, respectively (Table 1). The fragments were first cloned into
pGEM-T vectors and sequenced to confirm that there were no additional mu-
tations in Nsp15. The BamHI-KpnI fragments were then excised from pGEM-T
and subcloned into BamHI-KpnI-digested pcDNA3.1() (Invitrogen, Carlsbad,
CA) to generate plasmids pcD-mNsp15 and pcD-sNsp15, respectively (Table 2).
This placed mNsp15 and sNsp15 under the control of the cytomegalovirus im-
mediate-early promoter in pcDNA3.1. The SARS-CoV Nsp15 protein was also
tagged with an N-terminal Myc epitope by adding the sequence to the oligonu-
cleotide primer (Table 1). One million DBT cells seeded in each well of a six-well
plate were transfected with either pCDNA3.1(), pcD-mNsp15, or pcD-sNsp15
by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as recommended by the
manufacturer. Thirty hours later, the cells were infected with the H262A mutant
virus (vH262A) or WT virus at an MOI of 1. Metabolic labeling of the MHV
plus-strand RNAs was conducted at 6 hpi using the protocol described above. As
a control, a pcDNA3.1 plasmid encoding green fluorescent protein (GFP) con-
jugated to the N terminus of sNsp15 was constructed and named pcD-GFP-
sNsp15. GFP expression in DBT cells transfected with pcD-GFP-sNsp15 was
used as an indication of transfection efficiency and sNsp15 expression in DBT
cells.
RESULTS
Modeling of the active site of mNsp15. sNsp15 cleaves RNA
by a mechanism identical to that of RNase A (3, 21). To gain
insight into the mechanism of RNA cleavage used by the MHV
protein (mNsp15), we modeled the active site of mNsp15 com-
plexed with 3-UMP by using the coordinates from the crystal
structure of mNsp15 (PDB ID 2H85) and the molecular dock-
ing program Dock 6.0 (17). The best model has UMP oriented
so that the hydrogen-bonding face of uracil is contacted by
T321 of mNsp15 (Fig. 1A). The putative catalytic histidine,
H262 in mNsp15, is positioned to interact with the phosphate
of the UMP (corresponding to the cognate phosphodiester in
the substrate RNA), and H277 would interact with the ribose
2 hydroxyl moiety (Fig. 1A, left). These results are consistent
with the recognition of uridine by the active-site residues of
sNsp15 (Fig. 1A, center) as proposed by Ricagno et al. (21), as
FIG. 1. Biochemical analysis of mNsp15. (A) Molecular modeling of the active sites for mNsp15 and sNsp15. The UMP is indicated in yellow,
red, and blue, for carbon, oxygen, and nitrogen, respectively. (Left) The location of the UMP in mNsp15 was determined using the molecular
docking program Dock 6.0. (Center) The comparable residues in sNsp15 are shown with UMP. (Right) Superposition of sNsp15 catalytic-site
residues on mNsp15. (B) Recombinant mNsp15 WT and mutant proteins used in the biochemical analysis. The purified proteins were separated
on a 4-to-12% acrylamide–sodium dodecyl sulfate gel and stained with Coomassie brilliant blue. (C) Gel-based analysis of the endoribonuclease
activities of sNsp15 and mNsp15. Lanes C, uncleaved 13-nt TRS RNA substrate containing a single uridylate. The amount of protein added to the
reaction mixture, in nanograms, is given above each lane, as well as the identity of the WT or mutant protein. Arrows identify the Nsp15 cleavage
products.
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well as with the proposed cleavage mechanism that results in
the formation of a 2-3 cyclic phosphodiester on the RNA
product (2). In fact, despite some differences between the
amino acid residues in the two catalytic pockets, the two active
sites are virtually superimposable (Fig. 1A, right).
Our modeling studies also predicted that G275 in mNsp15
would contribute to the active sites in two ways. First, the G275
backbone nitrogen should add to the anionic charge of that
face of the active site. Second, the small hydrogen R group of
G275 is needed to sterically accommodate UMP; substitution
of the bulkier alanine should cause the C atom to disrupt
interactions between the catalytic histidine residues and UMP.
Modeling of the mNsp15 active site with an alanine in place of
the glycine at position 275 revealed that UMP could no longer
be docked (data not shown).
Biochemical characterization of mNsp15. To allow func-
tional comparison of sNsp15 and mNsp15, mutants with alter-
ations of residues H262, H277, and G275 in mNsp15 were
constructed (Fig. 1B). WT mNsp15 and the three mutant pro-
teins with single amino acid substitutions in the catalytic
pocket (H262A, G275A, H277A) were tested for their abilities
to cleave an RNA substrate containing the SARS-CoV TRS
for sgmRNA3 by a gel-based endoribonuclease assay. The
13-nt TRS substrate contains uridylate at the fifth position
from the 5 terminus. Consistent with our previous report (10),
both sNsp15 and mNsp15 were able to generate the 5-nt prod-
uct expected from preferential cleavage at this uridylate, indi-
cating specificity for uridylates (Fig. 1C). Quantification of
cleared products from several gel-based assays showed that the
G275A and H277A proteins retained endoribonuclease activ-
ity at 2% and 10% (Fig. 1C), respectively, of WT mNsp15
enzymatic activity, while cleavage by the H262A protein was at
background for this assay (Fig. 1C and data not shown). Mu-
tations of the comparable catalytic histidines (H249A and
H234A) in sNsp15 significantly reduced endoribonuclease ac-
tivity (10). These results indicated that, in agreement with the
modeling studies, the catalytic residues comparable to those in
sNsp15 are also required for efficient endoribonuclease activity
of mNsp15.
To extend the comparisons of mNsp15 and sNsp15, we ex-
amined preferential cleavage of uridylates by using a fluores-
cent real-time endoribonuclease assay previously described by
Bhardwaj et al. (2) (Fig. 2A). This assay uses one of four
nucleic acid substrates, each of which contains a 5 fluorophore
paired with a 3 quencher and one ribonucleotide; the remain-
ing three nucleotides have deoxyriboses and cannot be cleaved
by RNases. When cleavage takes place, the dissociation of the
quenching group from the fluorophore results in fluorescence
intensity that can be measured in real time. For brevity, each
substrate is named by the cleavable ribonucleotide (e.g., rU
denotes the substrate with a uridylate). In our standard assay
performed with 0.04 M Nsp15, neither sNsp15, WT mNsp15,
nor any of the mNsp15 mutant proteins could cleave rA or rG
substrates (data not shown). As expected, however, both
sNsp15 and mNsp15 actively cleaved rU, at rates of 44.5 and
29.6 M s1, respectively. With the rC substrate, the rates of
hydrolysis were lower for both sNsp15 and mNsp15, although
the rate was higher for mNsp15 than for sNsp15 (5.8 versus 1.8
M s1, respectively). The ratio of rU to rC cleavage was
calculated to determine the specificity factor (SF). sNsp15 had
an SF of 25, while mNsp15 had an SF of 3.7 (mean from six
trials; range, 5 to 3). Therefore, while both enzymes preferen-
tially cleaved uridylates, sNsp15 had higher specificity for uri-
dylate than did mNsp15.
Mutations in the RNase A catalytic triad are known to affect
RNase activity by degrees rather than to abolish it altogether
(7). While the H277A and G275A mutants retained detectable
activity in the gel-based assay, the H262A mutant did not. The
lack of cleavage by the H262A mutant in this assay could
reflect an issue with the background level in the gel-based
assay. To determine whether the mutations in the catalytic
pocket completely abolished mNsp15 activity, we incubated
twice the normal concentration of WT mNsp15 and the H262A
mutant (each at 0.08 M) for the fluorescence-based assay and
monitored their activities over a 400-s period. We note that
Nsp15 is enzymatically active only as a hexamer (2, 10), and a
change in protein concentration will affect hexamer formation.
As a control, the hepatitis C virus Ns5B protein was added at
0.24 M with the rU substrate, and no increase in fluorescence
was observed (data not shown). The H262A mutant did indeed
release fluorescence from the rU substrate (Fig. 2B). Further
increases in the concentration of the H262A mutant resulted in
even more obvious rU cleavage (data not shown). Along with
FIG. 2. Results of a real-time fluorescent endoribonuclease assay
with sNsp15 and mNsp15. (A) Specificity for cleavage of rU or rC
substrates by sNsp15 and mNsp15. The cleavable uridylate or cytidy-
late in the substrate is identified by the letters rU or rC, respectively.
AFU, arbitrary fluorescence units. (B) Examination of the endoribo-
nuclease activities of the H262A and H262P H277A mutant proteins.
Endoribonuclease activity was tested at 0.08 M WT or mutant
mNsp15. The substrate used contains a cognate rU or rC, as indicted
on the right. (C) Purity of WT and H262PH277A mutant proteins
detected by silver staining (Amersham, Piscataway, NJ).
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the results for the G275A and H277A mutants from the gel-
based assay, our data suggest that none of the three mutations
in the mNsp15 catalytic pocket completely abolished the en-
doribonuclease activity of mNsp15.
To examine the effects of changes in the catalytic pocket
further, we expressed a protein that contains two mutations,
H262P and H277A. This mutant corresponds to a virus we
fortuitously obtained and characterized (see below). The
H262PH277A protein was expressed well and was purified
over three columns to apparent homogeneity, as determined
by silver-stained denaturing gel electrophoresis (Fig. 2C).
When tested in the fluorescent assay, the H262PH277A mu-
tant retained detectable endoribonuclease activity, although at
a slightly lower level than that of the H262A mutant (Fig. 2B).
These results confirm that mutations in the catalytic pocket of
mNsp15 significantly reduce, but do not completely abolish,
endoribonuclease activity.
In the real time assay, we used rC as a control and noticed
that the H262A mutant cleaved rC about as well as rU, while
the WT protein preferentially cleaved rU (Fig. 2A). Therefore,
we determined the SFs for the H262A and H262PH277A
mutants and found them to be 1.35 and 1.17, respectively.
These results demonstrate that the active-site mutations de-
creased the specificity of RNA cleavage relative to that for WT
mNsp15.
MHV with mutations in Nsp15. To examine the biological
effects of mutations in mNsp15, we assembled full-length
MHV-A59 1000 genomes containing H262A, G275A, and
FIG. 3. Plaque morphology and growth kinetics for mNsp15 mutant and WT viruses. (A) Cultures of BHK-R cells were electroporated with
full-length WT or mutant mNsp15 transcripts and seeded on DBT cells in 75-cm2 flasks. The progeny was plaque purified and amplified once in
DBT cells. Plaques from mNsp15 single- and double-mutant viruses and WT virus were produced in six-well plates seeded with L2 cells. Nonviable
D324A mutant genomes (gD324A) did not form any visible plaques. (B and C) Triplicate DBT cell cultures in a 96-well plate were infected at the
indicated MOI and harvested at the indicated times postinfection, and viral titers were determined by a plaque assay. Note that independent viral
isolates were used in panels B and C. (B) Growth curves of vH262A, vG275A, vH277A, and WT virus at an MOI of 0.5. (C) Growth curves of
vH262A, vG275A, vH277A, vH277AH262P, and WT virus at an MOI of 1.5.
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H277A substitutions in mNsp15 by in vitro transcription from
ligated cDNAs. We also attempted to assemble a virus with the
D324A mutation, since the corresponding substitutions in
HCoV and EAV have been reported to be lethal for virus
production (12, 20). BHK-R cells electroporated with the WT
genome or with genomes with the H262A, G275A, or H277A
mutation all developed CPE after 24 h. The same manipula-
tion with MHV gRNA carrying the D324A substitution did not
produce CPE, and no mutant virus was recovered in three
independent trials (Fig. 3A). In one of the experiments, we
incubated the electroporated cells at 34°C and 40°C in the
event that the mutation rendered the virus temperature sensi-
tive, but we still failed to obtain viral plaques (data not shown).
Thus, the MHV genome carrying the D324A substitution ap-
peared to be nonviable, consistent with the results of previous
studies of HCoV-229E and EAV (12, 19).
For clarity, the viruses are named with the letter “v” in front
of the mutation. Mutants vH262A, vG275A, and vH277A pro-
duced plaques similar to those of the WT virus (Fig. 3A). The
resultant viruses were recovered from the medium, plaque
purified, and expanded in DBT cells. Sequencing of RT-PCR
fragments containing mNsp15 confirmed that vH262A and
vG275A possessed only their expected single mutations in
mNsp15. From the electroporation to recover vH277A, we
obtained plaques of the intended mutant without other
changes in Nsp15. However, three of the independent plaques
had a second spontaneous mutation in mNsp15 (L291Q,
I250Q, or H262P). The virus with both the H277A and the
H262P mutation, named vH262PH277A, was characterized
further. The fact that we recovered single-mutant viruses for
all three intended mutations as well as several double mutants
indicated that a reduction in mNsp15 endoribonuclease activ-
ity is not lethal to MHV.
To quantify the effects of the mutations, we examined the
morphologies of the plaques from WT and mutant viruses on
monolayers of L2 cells. Plaque diameters for the single and
double substitution mutants were modestly reduced from those
for WT virus (Fig. 3A and Table 3; also data not shown).
Mutants vH262A, vG275A, vH277A, and vH262PH277A av-
eraged a 10 to 17% reduction in plaque diameter in compar-
ison to WT virus. Similar results were obtained with the per-
missive cell types 17CL-1 and DBT. In no case was the
difference in plaque diameter between the mutant and the WT
virus statistically significant (P 	 0.5).
The infectivities of the mutant viruses were analyzed further
by determining their titers in several independent plaque-
forming assays. Viruses were eluted from single plaques and
titered on L2 cells. The mutant vH262A produced only 12% of
the PFU of WT virus (Table 3). These results indicate that,
despite the similarity in plaque morphology, the mutant viruses
do not grow to the same level as the WT virus.
To confirm that the mutant viruses are defective in replica-
tion, the growth kinetics of WT and mutant viruses were de-
termined using an MOI of 0.5 to infect DBT cells. All three
mutants grew to lower titers (by as much as 1.5 log units) than
WT virus (Fig. 3B). The maximum titer reached by vH277A
was three- to fourfold higher than those of vH262A and
vG275A (Fig. 3B). Interestingly, the reduction in viral titer was
more pronounced after 12 hpi than at earlier times postinfec-
tion for all of the mutants. When the same experiment was
performed at an initial MOI of 1.5, the more-pronounced
reductions in the titers of mutant viruses after 12 h were again
observed, but the differences from the WT were smaller than
those observed in the experiments performed with an MOI of
0.5 (Fig. 3C). These results prompted us to examine the double
mutant vH262PH277A. Again, it had a slightly more pro-
nounced defect 12 h after the initiation of infection than the
viruses with single amino acid substitutions (Fig. 3C). Further-
more, vH262PH277A produced less infectious virus than the
single mutants.
RNA accumulation in cells infected with mNsp15 mutant
viruses. We examined whether one mode of viral RNA repli-
cation and/or transcription was differentially affected. MHV
gRNA and sgmRNAs were metabolically radiolabeled in the
presence of actinomycin D to suppress cellular transcription
and were then analyzed by denaturing gel electrophoresis (Fig.
4A). All mNsp15 single-mutant viruses synthesized reduced
amounts of gRNA and of all six sgmRNAs, but the relative
ratios for the RNAs were approximately the same as those
seen in a WT infection (Table 4). Mutant vH277A produced
only 56% of the total viral RNAs detected in WT-infected
cells. Mutants vH262A and vG275A had more-severe defects,
producing total virus-specific RNAs at 31 and 22% of the level
in WT-infected cells, respectively.
RT-qPCR was used to determine whether the altered
growth phenotype of vH262A could be attributed to a defect in
MHV minus-strand RNA synthesis. Expression levels of mi-
nus-strand gRNA1, sgRNA3, and sgRNA7 were evaluated in
DBT cells infected with vH262A or WT virus (Fig. 4B). At 8
hpi, cells infected with vH262A contained minus-strand
gRNA1, sgRNA3, and sgRNA7 at 62%, 52%, and 32%, re-
spectively, of levels in cells infected with the WT virus. Average
cycle threshold (CT) values for expression levels of the WT
viral minus-strand RNAs were 19.6 for gRNA1 (CT for
GADPH, 18.80), 20.1 for sgRNA3 (CT for GADPH, 19.40),
and 15.2 for sgRNA7 (CT for GADPH, 19.10). In parallel,
average CT values for expression levels of the vH262A viral
minus-strand RNAs were 20.4 for gRNA1 (CT for GADPH,
18.96), 20.1 for sgRNA3 (CT for GADPH, 19.7), and 15.2 for
sgRNA7 (CT for GADPH, 19.4). At 12 hpi, the expression
levels of vH262A minus-strand RNAs were less than 38% of
those in cells infected with WT virus. The more severe de-
crease in MHV minus-strand RNA synthesis at 12 hpi corre-
lates with the defect in viral titers observed for the mutant
viruses at this time (Fig. 3B and C).
TABLE 3. Titration and diameters of virus particles within single
plaques isolated from either H262A mutant virus or
MHV-A59 1000 in L2 cellsa
Virus Mean titer 
 SEb (%) Plaque diam (mm)c
MHV-A59 1000 5.64  105 
 0.80  105(100) 2.22 
 0.06
vH262A 6.76  104 
 1.77  104(12) 2.26 
 0.06
a WT virus or vH262A was isolated from 12 individual plaques formed on L2
cells by using Pasteur pipettes, resuspended in 1 ml of DMEM, sonicated three
times for 20 s at 35% power in a cup sonicator, and titered.
b From 12 plaques.
c Calculated as an average for at least 25 plaques.  is 0.05, and Tukey’s W
procedure was performed.
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S protein expression by mNsp15 mutant viruses. Based on
the reduced viral RNA levels, we expected that the mutant
viruses would express viral proteins at reduced levels. The S
protein was examined by Western blot analyses of lysates of
DBT cells infected with either a mutant virus or WT virus (Fig.
4C). Relative to that in WT virus-infected cells, S protein
accumulation by three single-substitution mutant viruses was
less than 27% at 8 hpi. At 10 hpi, similar defects in S protein
levels were also observed for vH262A and vG275A, but
vH277A-infected cells produced 70% of the S protein level
found in cells infected with WT virus. We did not pursue the
basis for this change in vH277A.
trans-Complementation of vH262A with Nsp15 proteins de-
rived from MHV-A59 and SARS-CoV. We wanted to deter-
mine whether Nsp15 could function in trans to complement the
observed defects. For this analysis, the MHV or SARS-CoV
Nsp15 WT coding sequence was cloned into pCDNA3.1 under
the control of the strong immediate-early cytomegalovirus pro-
moter. We also expressed an N-terminal fusion of GFP and
sNsp15 cloned into pCDNA3.1. The GFP-sNsp15 plasmid was
transfected into DBT cells, and expression was detected by
fluorescence microscopy (Fig. 5A). DBT cells were transfected
with either pCDNA3.1 or one of the two plasmids that express
MHV or SARS-CoV Nsp15. At 30 h posttransfection, the cells
were infected with either WT virus or vH262A. MHV-specific
RNAs were then detected by metabolic radiolabeling of cells
with 32Pi in the presence of actinomycin D (Fig. 5B). Consis-
FIG. 4. Effects of the mutations in mNsp15 on MHV-specific RNA
and S protein accumulation. (A) RNA synthesis in cells infected with
mNsp15 mutant viruses. Cells were infected with either an mNsp15
mutant virus or WT virus, and viral RNAs were metabolically labeled
as described in Materials and Methods. The labeled viral RNAs were
separated by formaldehyde agarose gel electrophoresis and visualized
by autoradiography. The positions of bands of gRNA and sgmRNAs 1
through 7 are indicated on the right. (B) Effects of the H262A substi-
tution in mNsp15 on MHV minus-strand RNA accumulation. Levels of
minus-strand RNAs produced by vH262A and WT virus were deter-
mined by RT-qPCR. The relative levels of minus-strand RNA were
determined from the threshold values normalized for GAPDH mRNA
expression (endogenous control), and then the WT virus value was
defined as 1.0. Error bars, standard errors of the means. The symbol 
stands for WT virus. The relative levels of expression of the MHV
minus-strand RNAs by vH262A (dotted bars) were compared with the
levels of expression by WT virus (shaded bars) (  0.05). The values
shown represent data from three independent experiments. A melting
curve showed that there was a single product in each RT-qPCR, and
agarose gel electrophoresis of RT-qPCR products confirmed the single
RT-qPCR products (data not shown). (C) Expression of MHV S pro-
tein by mNsp15 mutant viruses. DBT cells were seeded in a T25 flask,
incubated for 24 h, and infected with an mNsp15 mutant or WT virus
at an MOI of 1. Total proteins were extracted from the DBT cells at 8
and 10 hpi and were then analyzed in order to detect S protein syn-
thesized by mNsp15 mutant viruses and WT virus by using with a goat
polyclonal antibody against MHV S protein (31). As a control, expres-
sion levels of GAPDH in DBT cells were determined using mouse
anti-mouse GAPDH antibodies and HRP-conjugated anti-mouse IgG
antibodies.
TABLE 4. Relative molar amounts of virus-specific RNAs
synthesized in DBT cells infected with mNsp15
mutant viruses
RNA species
Relative molar amta (mean 
 SE)
vH262A vG275A vH277A MHV-A59 1000
RNA1 1 1 1 1
sgmRNA2 2.1 
 0.2 2.2 
 0.4 2.0 
 0.3 2.5 
 0.4
sgmRNA3 2.3 
 0.3 2.4 
 0.5 2.5 
 0.5 3.1 
 0.4
sgmRNA4 8.8 
 0.7 9.6 
 2.0 9.6 
 1.5 10.3 
 0.8
sgmRNA5 7.3 
 0.3 7.6 
 1.3 7.0 
 1.2 8.2 
 0.2
sgmRNA6 14.0 
 1.4 15.0 
 2.6 13.5 
 1.7 13.7 
 1.4
sgmRNA7 30.9 
 3.5 33.6 
 7.0 32.1 
 8.0 27.4 
 5.4
a Relative to the molar amount of RNA1.
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tent with previous observations, vH262A exhibited a defect in
the accumulation of all MHV plus-strand RNAs relative to
that for the WT virus in the presence of the empty vector (Fig.
5B, first and second lanes). However, coexpression of the
mNsp15 protein in cells infected with vH262A increased the
levels of all of the plus-strand RNAs 2.3-fold (from 18% to
41%) (Fig. 5B, third lane). This result was confirmed by two
other independent experiments, both of which showed a 1.5-
fold or better increase in the abundance of the MHV plus-
strand RNAs. Interestingly, expression of the sNsp15 protein
in trans did not affect the levels of RNAs produced by vH262A,
indicating that the SARS-CoV ortholog could not complement
MHV plus-strand RNA levels in trans. Expression of the
sNsp15 or mNsp15 WT protein had no obvious effects on the
plus-strand RNAs produced by WT virus in an independent
experiment (data not shown), demonstrating that expression of
mNsp15 in trans did not affect MHV infection.
To confirm the complementation of vH262A with the
mNsp15 protein in trans, titers of vH262A and WT virus were
determined in DBT cells that had been transfected with vector
only or with vector expressing mNsp15 or sNsp15 protein and
then infected with vH262A or WT virus (Table 5). At 24 hpi,
the cells were frozen at 80°C, thawed, sonicated, and clari-
fied; then the resultant supernatants containing either vH262A
or WT virus were titered. Mutant vH262A grown in DBT cells
trans-complemented with the mNsp15 protein had yields of
infectious virus 	3.6 times higher than those in cells trans-
fected with vector only or with sNsp15 protein. Along with the
results for MHV plus-strand RNA production, these results
demonstrate that MHV Nsp15 could act in trans in a step
necessary for MHV replication.
DISCUSSION
The Nsp15 proteins of coronaviruses such as HCoV-229E,
SARS-CoV, and infectious bronchitis virus have been charac-
terized as uridylate-specific endoribonucleases (2, 12). In this
work, we examined the effects of single and double amino acid
substitutions in the catalytic pocket of mNsp15 and determined
that endoribonuclease activity was significantly affected by the
mutations, consistent with the report of Xu et al. (28). How-
ever, residual endoribonuclease activity could still be detected
even with the double amino acid substitution. Mutant viruses
containing the same single or double amino acid substitutions
were apparently unaffected in plaque morphology, but the in-
fectious virus titer was reduced as much as 13-fold. There were
also corresponding decreases in the levels of MHV plus- and
minus-strand RNAs and the MHV S protein. Lastly, we dem-
onstrated that the mNsp15 protein could partially complement
the defect in mNsp15 mutant viruses.
Biochemical properties of MHV Nsp15. The catalytic pocket
of the MHV Nsp15 protein differed in several residues from
that of SARS-CoV. However, when a UMP substrate was
docked into the mNsp15 active site, the similarities between
mNsp15 and sNsp15 were obvious. For mNsp15, residues
H262, H277, and K317 form a catalytic triad that is superim-
posable with the comparable residues in sNsp15. The modeling
generated results that are consistent both with the substrate
interaction model proposed by Ricagno et al. (21) for sNsp15,
based on the well-studied RNase A catalytic triad, and with the
mechanism of RNA cleavage by Nsp15 (2). In addition, mod-
eling with UMP shows that G275, H277, K317, T321, and T368
of mNsp15 are in close proximity.
FIG. 5. RNA accumulation in Nsp15-trans-complemented DBT
cells infected with vH262A. (A) Detection of sNsp15 expression. DBT
cells were transfected either with vector only or with pcD-GFP-sNsp15
and were subjected to GFP detection by fluorescent microscopy of
cells at 30 h posttransfection. (B) DBT cells were first transfected
either with vector only or with a plasmid driving the expression
of Nsp15 derived from MHV-A59 or SARS-CoV (pcD-mNsp15 or
pcD-sNsp15) and then infected with vH262A or WT virus 30 h later.
At 6 hpi, viral RNAs were metabolically labeled as described in Ma-
terials and Methods. The labeled viral RNAs were resolved by form-
aldehyde agarose gel electrophoresis and visualized by autoradiogra-
phy. The identities of the MHV RNAs are given on the right.
TABLE 5. Titration of vH262A in trans-complemented DBT cells
Virus Transfection Titer (log10)(mean 
 SE)
MHV-A59 1000 Vector only 7.36 
 0.03
vH262A Vector only 6.31 
 0.06
mNsp15 6.98 
 0.02
sNsp15 6.41 
 0.01
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Some notable differences exist in the other side of the cat-
alytic cleft of mNsp15 and sNsp15. First, in sNsp15, residue
S293 is likely responsible for specific recognition of the uracil.
In mNsp15, residue T321 would serve as the specificity-deter-
mining residue (Fig. 1A). Second, the side chain oxygen atom
of T368 in mNsp15 forms a hydrogen bond with the C-4 keto
group of the UMP, while the comparable residue in sNsp15 is
Leu345. Third, a ribose ring in UMP can make two additional
hydrogen bond interactions with the side chain oxygen atoms
of E362 in mNsp15 (at 2.5 and 2.6 Å) compared to T340 in
sNsp15. The close positioning of the E362 side chain to the
ribose in UMP should impose some restriction on the binding
orientation. Fourth, the role of the C-terminal tail appears to
differ between sNsp15 and mNsp15. Residues Y342 and P343
of sNsp15 appear to form hydrophobic stacks with the uracil
and should stabilize UMP binding, while K365 and V366 would
take their place in mNsp15. K365 can engage in hydrophobic
interactions with the substrate through its side chain carbon
atoms.
The mNsp15 protein was found to preferentially cleave uri-
dylates, but the specific cleavage of uridylates was less stringent
than that of sNsp15. A change of residue H262 to alanine
resulted in a protein that can cleave uridylates and cytidylates
equally well (Fig. 2B). This observation was not made with the
orthologs from other nidoviruses (19, 21). At this point, we do
not understand the molecular basis for this difference. How-
ever, we speculate that the difference in the interaction be-
tween E362 and the C-terminal residues of mNsp15 with the
substrate could account for the slightly relaxed cleavage spec-
ificity of mNsp15. This model needs to be confirmed by further
biochemical analyses.
Recombinant mNsp15 was previously produced in E. coli by
Bhardwaj et al. (2) and was demonstrated to possess signifi-
cantly lower endoribonuclease activity than the corresponding
enzymes from SARS-CoV and infectious bronchitis virus. The
mNsp15 protein used in this study is more biochemically active
than the previous preparations (2). A basis for this difference
is that the mNsp15 made previously contained His6 tags at both
the N and C termini, while the version in this work contained
only an N-terminal His6 tag. In the fluorescent real-time assay,
we observed that the doubly tagged protein cleaved substrates
at uridylates and cytidylates approximately equally well, with a
specificity ratio of 1 rather than the ratio of 3 found for the
N-terminally tagged mNsp15 (data not shown). Since the C
termini of sNsp15 and mNsp15 contribute to the formation of
the active sites, we now appreciate that additional residues at
the C terminus of Nsp15 could significantly affect Nsp15 en-
doribonuclease activity and specificity.
Nsp15 and MHV infection. Recombinant MHVs harboring
either the single substitution H262A, G275A, or H277A or two
mutations (H277A and H262P) in mNsp15 were infectious and
produced plaques in L2, DBT, and 17CL-1 cells with a mean
diameter of approximately 80% of that for MHV-A59. We had
expected a greater effect of mutations in mNsp15 on MHV
infectivity. However, it should be noted that reduced enzymatic
activity was retained with all the mNsp15 mutant proteins (Fig.
2C and data not shown). Furthermore, mNsp15 with two mu-
tations in the catalytic pocket had the least endoribonuclease
activity, and vH262PH277A produced less infectious virus
than the mutants with single amino acid substitutions. We posit
that the reduced endoribonuclease activity of mutant versions
of Nsp15 is responsible for the reduced virus production. The
observation that genomes containing the D324A substitution
were nonviable further supports a claim for an essential role of
Nsp15 in MHV infection; molecular modeling predicts that
D324 is critical for maintaining a network of ionic bonds, and
the change to alanine resulted in an insoluble protein (data not
shown). In any case, the fact that mutations in Nsp15 reduced
the level of infection by as much as 2 log units clearly shows
that the Nsp15 endoribonuclease is needed for optimal MHV
replication.
MHV Nsp15 mutant viruses have distinguishable features in
plaque formation and viral RNA synthesis compared to EAV
mutants with similar mutations. For example, the EAV mutant
virus containing a mutation (H2963A) comparable to H262A
in mNsp15 produced plaques with only 20% of the diameter of
WT virus plaques (19). We note that in our experiments with
MHV, similar results were observed with all of the cells tested
(L2, DBT, and 17CL-1). In particular, 17CL-1 cells have been
reported to produce interferon (1, 29). Thus, mutations in
mNsp15 cannot be easily distinguished by plaque morphology
alone, and the reduction of mNsp15 activity did not abolish
plaque formation in interferon-positive cells. Nonetheless, the
widespread defect in MHV gene expression caused by muta-
tions in mNsp15 did not allow us to determine whether
mNsp15 acts on one particular process required for viral in-
fection.
Lastly, this study showed that two mNsp15 mutant viruses
were partially complemented in trans for MHV plus-strand
RNA synthesis and infectious particle production by expres-
sion of mNsp15 in DBT cells. Thus, mNsp15 forms another
complementation group in MHV-A59 open reading frame 1b
(23). Based on these results, future assessments of the corre-
lation between activities of Nsp15 could be performed by ex-
pression of Nsp15 in trans rather than by the more laborious
method of making recombinant viruses. It is also of interest
that sNsp15 could not complement the mNsp15 mutation in
trans. We cannot completely rule out the possibility that the
failure of sNsp15 to complement mNsp15 mutations is due to
lower levels of expression of sNsp15 than of mNsp15. How-
ever, the higher enzymatic activity of sNsp15 relative to
mNsp15 makes it unlikely that our trans-complementation re-
sults are due to lower levels of enzymatic activity in cells trans-
fected with the sNsp15 expression plasmid. Rather, we suggest
that mNsp15 may need to specifically interact with other
MHV-specific molecules.
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